前列腺癌高剂量率近距离放疗联合外照射后PSA闪烁提示良好预后
该研究分析了623例1995至2008年间接受高剂量率近距离放疗(HDR-BT)联合外照射放疗(ERT)的前列腺癌患者的PSA闪烁情况。PSA闪烁定义为PSA暂时性升高>0.2 ng/ml,发生率为26%(159例)。在多因素Cox回归中,PSA闪烁与较低的PSA失败风险相关(HR=0.42;95%CI 0.26-0.70)。作者结论认为PSA闪烁常见且与良好预后相关,应提醒临床医生不要过早启动挽救治疗。
要点
- 623例接受HDR-BT联合ERT的前列腺癌患者中,26%(159例)出现PSA闪烁(暂时性升高>0.2 ng/ml)。
- PSA闪烁与较低的PSA失败风险独立相关(HR=0.42;95%CI 0.26-0.70)。
- 作者提醒:早期PSA闪烁后复发风险很低,临床医生不应过早启动挽救治疗。
核心结论
- HDR-BT联合ERT后PSA闪烁常见,且与良好预后相关;早期PSA闪烁后复发风险很低,作者提醒临床医生不应过早启动挽救治疗。
研究设计与样本
- 回顾性分析1995至2008年间接受HDR-BT联合ERT的623例前列腺癌患者,中位年龄66岁(范围47-79),中位初始PSA 12 ng/ml(范围0.1-224),429例接受新辅助内分泌治疗。
- ERT采用2 Gy分次至50 Gy,HDR-BT采用两次10 Gy分次;中位随访11年(范围2-266个月)。
- PSA闪烁定义为PSA暂时性升高>0.2 ng/ml;PSA失败按Phoenix定义。
主要发现
- PSA闪烁发生于159例(26%),其中56例闪烁幅度>2 ng/ml,31例出现多次闪烁。
- 至闪烁峰值的中位时间为15个月(范围3-103),中位闪烁值为1.5 ng/ml(范围0.3-12)。
- 较年轻年龄和较低Gleason评分与PSA闪烁相关。
- 以PSA闪烁为时间依赖协变量并校正其他预后因素的Cox回归分析显示,PSA闪烁与较低的PSA失败风险相关(HR=0.42;95%CI 0.26-0.70)。
关键数值与推荐
- PSA闪烁定义:PSA暂时性升高>0.2 ng/ml。
- PSA失败定义:按Phoenix定义。
- PSA闪烁与PSA失败风险的HR=0.42(95%CI 0.26-0.70)。
临床怎么用
- 作者结论认为,早期PSA闪烁后复发风险很低,临床医生不应过早启动挽救治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: PSA kinetics after curative radiotherapy for prostate cancer is an important part of the posttreatment evaluation. We analysed PSA bounce occurrence after combined high dose rate brachytherapy (HDR-BT) and external radiotherapy (ERT). MATERIAL & METHODS: We analysed 623 patients treated from 1995 to 2008. The median age was 66 years (47-79). The median initial PSA was 12 ng/ml (0.1-224). Neoadjuvant endocrine therapy was given to 429 patients. ERT was given with 2 Gy fractions to 50 Gy and HDR-BT in two 10 Gy fractions. The median follow-up was 11 years (range 2-266 months). PSA bounce was defined as a temporary rise in PSA >0.2 ng/ml. PSA failure was defined according to the Phoenix definition. RESULTS: PSA bounce occurred in 159 patients (26%), where 56 patients had a bounce amplitude >2 ng/ml and 31 patients had multiple bounces. Median time to bounce peak was 15 (3-103) months with a median bounce value of 1.5 (0.3-12)ng/ml. Younger age and lower Gleason scores were associated with PSA bounce. In a Cox regression analysis with PSA bounce as a time-dependent covariate and adjusted for other prognostic factors, PSA bounce was associated with a lower risk for PSA failure (HR = 0.42; 95% confidence interval 0.26-0.70). CONCLUSION: PSA bounce after HDR-BT combined with ERT is common and associated with a good prognosis. As the relapse risk after an early bounce is very low, the findings should alert clinicians not to initiate salvage treatment too early. Research in prospective identification of PSA bounce is clinically relevant.
引用
- Åström L, Sandin F, Holmberg L, et al. Good prognosis following a PSA bounce after high dose rate brachytherapy and external radiotherapy in prostate cancer. Radiother Oncol. 2018. PMID: 30193693. doi:10.1016/j.radonc.2018.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。